camurus ab publ swedish researchbased pharmaceutical biotechnology company specialising commercialization medicines treating serious chronic diseases established based southern university city lund medicon valley region company listed nasdaq stockholm mid cap camurus founded scientists biophysical food pharmaceutical chemistry expertise lipid phase structures company provides innovative nanoscale drugdelivery systems development highvalue therapeutics camurus aims collaborate biotechnology pharmaceutical companies worldwide enable improve delivery wide range drug compounds compounds including peptides proteins insoluble small molecules make use delivery solutions ranging longacting depots lipid nanocarriers designed improved intravenous transdermal oral delivery camurus inhouse product portfolio targets healthcare needs areas growthhormone disorders cancer oncology supportive care metabolic disease drug addiction british investors evaluated six nominated private companies chose camurus best privately owned biotechnology company medicon company awarded strictly financing award camurus awarded cphi pharma award best innovation camurus company focused development lipid lyotropic liquid crystal structures pharmaceutical drug delivery applications structures welldefined threedimensional formations consisting lipophilic hydrophilic domains either interconnected isolated depending environmentally induced phase unique crystalline structures offer unique way encapsulating transporting active pharmaceutical ingredients small molecules peptides proteins body structures also allow use controlled release prevention degradation fragile short half live molecules serious issue aminoacid based drugs camurus fluidcrystal available injectable depots topical bioadhesive delivery technologies encapsulating drug compound nanostructures injectable depots able deliver therapeutic levels drug substance extended periods single injection leads decrease traditional side effects associated high initial drug release injection drug burst poor drug stability complex processing requirements making system highly suitable sustained parental delivery peptides proteins small molecule drug topical delivery system creates bioadhesive film provides local continual release drug compounds delivery system suited delivery peptide protein small molecule drug compounds applied dermal buccal ophthalmic nasal vaginal topical surfaces camurus partnered colgatepalmolive marketing elyzol dental gel treatment elyzol dental gel contains metronidazole form metronidazole benzoate active substance metronidazole antibiotic active organisms predominant subgingival flora adult periodontitis affect helpful aerobic oral mucositis severe sideeffect chemotherapy radiotherapy cancer treatment often doselimiting factor treatment episil administered lipidbased liquid spreads intraoral mucosal surfaces transforms strongly bioadhesive fluidcrystal film mechanically protects sensitized sore epithelium oral demonstrated several clinical trials episil gives immediate significant reduction pain analgesic effect maintained least hours following administration treatment reported safe well tolerated product registered medical device wide range countries including european union united states product treatment acromegaly carcinoid tumours assessed double blind randomized parallelgroup placebo controlled phase trial partnered novartis new drug developed longterm treatment prostate cancer development also initiated endometriosis camurus completed phase iia clinical trial patients advanced metastatic prostate cancer represents new treatment concept opiate addiction based welldocumented antiaddiction therapeutic buprenorphine developed sustained release injection depot httpsenwikipediaorgwikicamurus